Amplification of the EGFR gene was the first reported genetic alteration described in glioma and is associated with gene rearrangements [1]. The first rearrangement to be described in detail was an extracellular domain deletion known as the de2-7 EGFR (epidermal growth factor receptor) (or EGFRvIII) [2, 3] 
Introduction

Amplification of the EGFR gene was the first reported genetic alteration described in glioma and is associated with gene rearrangements [1]. The first rearrangement to be described in detail was an extracellular domain deletion known as the de2-7 EGFR (epidermal growth factor receptor) (or EGFRvIII) [2, 3]. Numerous subsequent studies have shown this to be the most common mutation in glioma, occurring in about 50% of cases where the EGFR gene is amplified [4]. This cancer-specific EGFR mutant has a specific deletion between exons 2 and 7 of the EGFR. The truncation of exons 2-7 leads to the elimination of 267 amino acids from the extracellular domain and the insertion of a novel glycine at the fusion junction and renders the mutant EGFR unable to bind any known ligand [5, 6]. Despite this, the de2-7 EGFR is capable of a low level of constitutive signalling that is augmented by the receptor's impaired internalization and down-regulation
. [25] . Thus our method of analysis provided the expected outcome for a previously described EGFR therapeutic antibody. [26] . Vehicle [29, 30] . A431 xenografts were treated with mAb 806, BAY 11-7085 or combination therapy (Fig. 3c) . Survival analysis showed significant differences across the four groups (Fig. 3c, P Ͻ 0 [31] [32] [33] , the inhibitor of Cyclin Kinase 2. (Fig. 3d) . Survival analysis showed a significant difference across the 4 groups ( Fig. 3d, P Ͻ [36] . 
Monoclonal antibody (MAb) 806 is a novel EGFR antibody that was generated by immunizing with cells expressing the de2-7 EGFR, but unexpectedly, it also bound a small proportion of the wild-type (wt) EGFR in tumours and cell lines that overexpress the receptor [8]. Not surprisingly then, mAb 806 does not bind the unique junctional peptide found at the site of the de2-7 EGFR mutation; instead it binds to a short cysteine loop in the extracellular domain of the EGFR that is only transiently exposed as the wt EGFR moves from its inactive to active conformation [9]. The loop is constitutively exposed in the de2-7 EGFR, consistent with our
Results and discussion
The ability of mAb 806 to influence both VEGF and IL-8 expression led us to examine its effect on the NF-B pathway, as its activation can induce both of these angiogenic factors
Importantly, this induction of p21 inA431 cells is dependent on activation NF-B [31], firmly establishing a anti-proliferative role for NF-B in these cells. Furthermore, a more general role for NF-B as a tumour suppressor in some instances is now well established [34]. Interestingly, a microarray analysis of the mRNA modulated by a small molecule weight inhibitor specific to the EGFR (PD153035) showed that it reduces the invasiveness of cervical carcinoma cells and this was associated with the activation of NF-B [35]. The in vivo consequences were not examined in this study. Finally, while seemingly unlikely, it would be interesting to determine if mAb 806 retained its vascular normalization activity in the presence of BAY11-708. Given the increase in VEGF seen with mAb 806 therapy, we treated A431 xenografts with vehicle, mAb 806, bevacizumab (an anti-VEGF antibody) or combination therapy
log rank). The median survivals were 21 days (control), 24 days (mAb 806), 34 days (bevacizumab) and not reached (combination). The control group did significantly worse than all other groups. The combination group did significantly better than either of the single agent's arms (P Ͻ 0.05 for both comparisons). Hence, there is additional therapeutic benefit in combining mAb 806 with a conventional anti-angiogenic agent that potently reduces the level of VEGF and MVD
MAb 806 binds a distinct epitope on the EGFR leading to distinctive outcome compared to ligand-inhibitory antibodies [37]. It inhibits tumours overexpressing wtEGFR by activating the NF-B pathway. Consistent with NF-B activation, mAb 806 induced expression of both VEGF and IL-8. Associated with these changes in angiogenic factors, we also observed that mAb 806 normalized tumour vasculature, profoundly reducing tumour hypoxia. This suggests the clinical development of mAb 806 could include combination with standard treatments for cancer. Pretreatment with mAb 806 may enhance radiotherapy by reducing intratumour hypoxia or improve the penetration of chemotherapy by increasing perfusion. Although it is theoretically possible that the improved tumour vasculature and perfusion mediated by mAb 806 may increase the supply of nutrients and growth of tumours, this is negated by the direct anti-proliferative effects of mAb 806. This study also confirmed that combining of mAb 806 with © 2009 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 3 In vivo function of NF-B and VEGF on mAb 806 anti-tumour activity. Treatment with mAb 806 significantly increases nuclear NF-B DNA (a) as measured by ELISA or (b) Western blot of the p65 subunit. (c) Survival curves using a combined end-point of moribund condition or
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